A new automated digital pathology algorithm, known as the uPath PD-L1, could speed diagnosis and targeted treatment decisions for patients with NSCLC, according to a press release. 

The uPath PD-L1 is an image analysis tool that automatically assesses scanned slide images. 

The manufacturer also said the algorithm “uses automated pre-computing and one-click scoring to enable quicker and accurate detection…” 

The algorithm is ready to use on the Roche uPath enterprise software platform.  

The efficacy of the diagnostic algorithm was validated using the VENTANA PD-L1 (SP263) Assay. 

“Improving diagnostic consistency and certainty is crucial in providing faster, higher-quality and more accurate diagnoses to cancer patients. Our uPath PD-L1 (SP263) image analysis [NSCLC] is the first next-generation CE-IVD PD-L1 algorithm to the clinical market. It expands on our growing digital pathology suite for VENTANA assays that aid physicians in providing the most accurate treatment decisions for patients with the most common type of lung cancer.” 

Thomas Schi-necker, CEO, Roche Diagnostics, said in a press release. 

According to the manufacturer, the new algorithm will enable clinicians to determine the PD-L1 status of a tumor. 

PD-L1 targeted therapy decisions can then be made for patients based on the test results. The manufacturer also noted the ease-of-use associated with the new algorithm. 

“The algorithm’s whole-slide automated analysis uses artificial intelligence to provide, with one-click, an actionable assessment of the scanned slide images that is objective and reproducible,” they wrote. 


By MD /alert staff